Korea University Medicine Study Identifies a New Biomarker for Major Depressive Disorder

Korea University Medicine Study Highlights a New Biomarker for Major Depressive Disorder The human brain, specifically its outermost cortex, is riddled with folds or 'gyri' essential for its proper functioning. Unsurprisingly, therefore, abnormal gyrification i.e., the development of gyri, can manifest as serious neurological disorders, including the highly disabling and widespread mental illnes..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Seelos Therapeutics Closes Enrollment of Study for Intranasal Ketamine Treatment for Acute Suicidal Ideation and Behavior in Major Depressive Disorder Patients

Seelos Therapeutics has completed enrollment in its registration-directed study of SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation and behavior (ASIB) in adults with major depressive disorder (MDD). The two-part clinical trial includes an open-label cohort followed by a randomized, double-blind, placebo-controlled study. Seelos aims to address the unmet need for ther..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen has announced the results of a successful US Phase 1 study of Itruvone (PH10), which enables the drug's development for treating major depressive disorder. The U.S. Phase 1 clinical trial was a randomized, double-blind, placebo-controlled clinical study investigating the safety and tolerability of a single dose and multiple doses of itruvone nasal spray in healthy adult subjects. The po..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms